$-0.09
(Market cap
$20 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
--
P/B Ratio
0.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
153.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.9
-
Face value
--
-
Shares outstanding
8,244,253
10 Years Aggregate
CFO
$-134.94 Mln
EBITDA
$-143.33 Mln
Net Profit
$-151.91 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lipocine (LPCN)
| -70.6 | 10.8 | 15.1 | -18.3 | -13.5 | -35.7 | -27.2 |
|
BSE Sensex*
| -11.7 | -4.8 | 1.7 | -7.5 | 3.9 | 5.1 | 9.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Lipocine (LPCN)
| 64.5 | 74.1 | -58.7 | -59.8 | -27.1 | 253.3 | -70.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Lipocine (LPCN)
|
2.4 | 20.2 | 1.6 | -11.9 | -755.1 | -65.4 | -- | 0.9 |
| 85.1 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 270.1 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 75.4 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 57.7 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 108.3 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 351.3 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 116.5 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 534.2 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 590.9 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 |
Shareholding Pattern
View DetailsAbout Lipocine (LPCN)
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT)... comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management. In addition, the company is developing LPCN 2201, an oral brexanolone formulation that has completed a Phase 1 trial for major depressive disorders; LPCN 2203, an oral candidate that has completed a Phase 1 trial for management of essential tremor; and LPCN 2101, a neuroactive steroids (NAS) candidate that has completed a Phase 1 trial for drug-resistant epilepsy and women with epilepsy. The company's products focus on neurological and psychiatric central nervous system (CNS) disorders, liver disease, and hormone supplementation in the United States. It has a collaboration with Verity Pharmaceuticals, Inc. to develop and commercialize TLANDO; and TLANDO XR (LPCN 1111), a once-daily oral product candidate that has completed a Phase 2 trial for testosterone replacement therapy. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah. Read more
-
Co-Founder, Interim Principal Financial Officer, Director, President & CEO
Dr. Mahesh V. Patel Ph.D.
-
Co-Founder, Interim Principal Financial Officer, Director, President & CEO
Dr. Mahesh V. Patel Ph.D.
-
Headquarters
Salt Lake City, UT
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Lipocine (LPCN)
What is the current share price of Lipocine Inc (LPCN) Today?
The share price of Lipocine Inc (LPCN) is $2.36 (NASDAQ) as of 08-Sep-2026 16:00 EDT. Lipocine Inc (LPCN) has given a return of -13.53% in the last 3 years.
What is the current PB & PE ratio of Lipocine Inc (LPCN)?
Since, TTM earnings of Lipocine Inc (LPCN) is negative, P/E ratio is not available.
The P/B ratio of Lipocine Inc (LPCN) is 0.91 times as on 04-Sep-2026, a 83 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-4.76 |
3.17 |
2024 |
3,168.38 |
1.26 |
2023 |
-0.91 |
0.73 |
2022 |
-0.19 |
0.06 |
2021 |
-8.17 |
0.11 |
What is the 52 Week High and Low of Lipocine Inc (LPCN)?
The 52-week high and low of Lipocine Inc (LPCN) are Rs 12.37 and Rs 1.81 as of 09-Sep-2026.
What is the market cap of Lipocine Inc (LPCN)?
Lipocine Inc (LPCN) has a market capitalisation of $ 20 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Lipocine Inc (LPCN)?
Before investing in Lipocine Inc (LPCN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.